Pharmaceuticals, Biotechnology and Life Sciences
4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest…
COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an…
Company announcement no. 8 – 24 18 September 2024 NTG Nordic Transport Group acquires ITC Logistics NTG Germany GmbH (“NTG”),…
Annual Conference in Orange County Will Showcase Latest Bioscience Advancements in AI, Diagnostics, Therapeutics, Digital Health, Implantable and Wearable Medical…
SPRING, Texas, Sept. 18, 2024 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., presented results from studies done on the potential for…
Successful feasibility study underscores compatibility of STAR-LLD using On-body Injector (OBI) technology and Starton’s proprietary low-dose formulation of lenalidomide (LLD)Based…
Company dedicated to providing a new hope for patients with treatment-resistant gynecological cancers Lead program, KAD101 for the treatment of…
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into…
Selskabet annoncerede i selskabsmeddelelse 13/2024, at man havde indledt en proces med at gennemføre et identitetsskifte med Nasdaq for fortsat…
Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known to increase ovarian cancer risk six-fold and risk of aggressive subtypes of breast cancer four-fold. They found over 3,000 harmful genetic changes that could potentially disrupt its function and increase cancer risk. These findings were confirmed by analysing data from large-scale health databases.